Publication date: Aug 23, 2024
Poor post-vaccination production of antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a concern among solid organ transplant (SOT) recipients. Furthermore, the timing and kinetics of antibody titers after the second vaccine dose are unknown. We conducted a multicenter prospective observational study that included 614 SOT recipients: 460 kidney, 53 heart, 50 liver, 20 lung, and 31 simultaneous pancreas-kidney (SPK). The participants received two doses of the mRNA vaccine (Pfizer BNT162b2 or Moderna mRNA-1273), as indicated. Serum samples were collected before the first and second vaccinations and at 1, 3, and 6 months after the second vaccine dose, which were then assessed for SARS-CoV-2 antibodies. The overall seropositivity rate was 43% at 1 month after administration of the second vaccine dose; it gradually increased to 68% at 3 months after second dose administration and to 70% at 6 months. In addition, recipient of kidney, lung or SPK transplants had lower antibody titers at the 3- and 6-month time points than did the other recipients. SOT recipients acquired SARS-CoV-2 S-IgG antibodies slowly, and the peak titer differed significantly from that of the general population.
| Concepts | Keywords |
|---|---|
| Bnt162b2 | Immunosuppressive therapy |
| Coronavirus | Post-vaccination antibody |
| Kidney | Prospective cohort study |
| Moderna | SARS-CoV-2 vaccine |
| Severe | Solid organ transplantation |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | VO | dose |
| disease | VO | vaccine |
| disease | VO | vaccination |
| disease | IDO | production |
| disease | VO | Severe acute respiratory syndrome coronavirus 2 |
| disease | VO | vaccine dose |
| disease | VO | time |
| disease | VO | titer |
| disease | VO | population |